Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study

The surprising results published by FIRE-3 revealed that the overall survival (OS) of RAS wild-type metastatic colorectal cancer (mCRC) patients treated with Cetuximab(Cmab) and FOLFIRI combination was prolonged to 33.1 months. The substantial increase in testing and treatment costs, however, impose...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Biol Ther
Hauptverfasser: Wen, Feng, Yang, Yu, Zhang, Pengfei, Zhang, Jian, Zhou, Jing, Tang, Ruilei, Chen, Hongdou, Zheng, Hanrui, Fu, Ping, Li, Qiu
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis 2015
Schlagworte:
Clinical Study
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4846122/
https://ncbi.nlm.nih.gov/pubmed/26418570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2015.1095398
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge